SPRYCEL®

Drug Information Related Patent

Hold Company

BRISTOL MYERS SQUIBB

Learn More

Dosage and Administration

TABLET;ORAL

Specification

20MG; 50MG; 70MG; 100MG; 80MG; 1400MG

Indication

SPRYCEL® is a cancer medicine that slows the growth and spread of cancer cells in the body. Sprycel is used in adults and children to treat a type of blood cancer called Philadelphia chromosome-positive chronic myelogenous leukemia (CML). Sprycel is also used to treat Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) in adults and children.

Use

Instructions for Use

API

DASATINIB

API Structure

We Supply

DASATINIB

Note:

Facility GMP
China DMF/FDA

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
7491725	2026/3/28
7491725*PED	2026/9/28
8680103	2025/2/4
8680103*PED	2025/8/4

API Patent

Patent No	Expiration Date
7491725	2026/3/28
7491725*PED	2026/9/28
8680103	2025/2/4
8680103*PED	2025/8/4

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION